Drug Profile
Gimatecan - Lee's Pharmaceutical
Alternative Names: CPT-184; LBQ 707; NVP-LBQ707; ST-1481Latest Information Update: 30 Jan 2024
Price :
$50
*
At a glance
- Originator Istituto Nazionale per lo Studio e la Cura dei Tumori; sigma-tau SpA
- Developer Lee's Pharmaceutical; Novartis; sigma-tau SpA
- Class Antineoplastics; Benzylisoquinolines; Camptothecins; Heterocyclic compounds with 4 or more rings; Imines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Preclinical Precursor B-cell lymphoblastic leukaemia-lymphoma
- No development reported Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Discontinued Glioma; Myelodysplastic syndromes
Most Recent Events
- 09 Dec 2023 Phase-II clinical trials in Solid tumours (PO) prior to December 2023
- 09 Dec 2023 Preclinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma in Hong Kong (PO) prior to December 2023
- 09 Dec 2023 Pharmacodynamics and adverse events data from a preclinical study in Precursor B-cell lymphoblastic leukaemia lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)